Therapeutic Intervention of Corticospinal Tract Sprouting after Unilateral Traumatic Brain Injury via METTL1-Mediated tRNA m7G Modification

分享:

简介:

  • 作者: Zhenpeng Li, An Jiang, Bengang Qin, Jintao Fang, Xubo Li, Fanbin Gu, Wenting He, Liwei Yan, Jiantao Yang, Canbin Zheng, Qingtang Zhu & Honggang Wang
  • 杂志: Molecular Neurobiology
  • Doi: https://www.doi.org/10.1007/s12035-025-05599-6
  • 出版日期: 2025/12/12

论文中使用的产品/服务

询价

摘要

Corticospinal tracts (CST) from the contralateral side spontaneously sprouting into the denervated motor neurons in the impaired spinal hemicord allow the contralateral motor cortex to control the paralyzed limb, improving the impaired limb function after unilateral brain injury. However, the intrinsic potential for axon outgrowth in adults is limited, restricting the functional recovery through CST sprouting. While ribosomal RNA modification has been reported in regulating CST sprouting, the role of transfer RNA (tRNA) modifications remains unclear. Here, we investigated METTL1, the methyltransferase for tRNA m7G modification, as a potential regulator of CST sprouting. In a mouse model of unilateral traumatic brain injury, we found overexpression of METTL1 in contralesional corticospinal neurons improved motor function recovery and promoted CST sprouting. Mechanistically, METTL1 upregulates tRNA m7G modification level, which augments the translation efficiency of mRNAs associated with axon outgrowth, particularly those within the mTOR signaling pathway. Critically, pharmacological inhibition of mTOR signaling with rapamycin diminishes the beneficial effects of METTL1 overexpression on axon outgrowth and CST sprouting. Our findings reveal a novel role for METTL1-mediated tRNA m7G modification in promoting neural repair and identify a potential therapeutic strategy for enhancing recovery after unilateral brain injury.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载

用户登录

还没账号? 请注册
手机验证码登录
账号密码登录
手机号码*
验证码*
忘记密码?

首次使用手机号登录将自动为您注册

登录即代表阅读并接受《注册协议》 《用户协议》

新用户注册

已有账号?
手机注册
邮箱注册
手机号码*
验证码*
机构名称*
客户类型*

重置密码

手机找回密码
邮箱找回密码
手机号码*
验证码*
设置新密码*
确认新密码*